|
|
|
|
|||||||
| Funding, Legislation, & Advocacy Funding and fundraising, legislation, and advocacy |
 |
|
|
Thread Tools | Display Modes |
01-23-2006, 05:58 PM
|
#1 | |
|
Administrator
Join Date: Jul 2001
Location: New Brunswick, NJ, USA
Posts: 37,975
|
A Review of 18 Companies That Have the Ability to Make a Difference in the Stem Cell
http://www.marketwatch.com/news/news...tegories=&
Quote:
Companies Mentioned Aastrom Biosciences Inc. Advanced Cell Technology Inc. Amgen Amersham AstraZeneca Biogen Idec BresaGen Ltd. Cell Genesys Cellartis AB Cellular Dynamics International Ceregene, Inc. Covance Cytori Therapeutics, Inc. Genentech Genesys Inc. Genzyme Geron Corporation Incyte Johnson & Johnson Layton Bioscience Inc. Merck Novartis AG Novocell, Inc. NsGene A/S Quintiles ReNeuron Group plc Schering AG Stem Cell Therapeutics Corp. StemCells Inc. Titan Pharmaceuticals Inc. Transition Therapeutics Inc. TriStem Corporation ViaCell Inc. [/quote] |
|
|
|
|
01-23-2006, 07:52 PM
|
#2 |
|
Senior Member
Join Date: Jun 2005
Location: Norway
Posts: 17,367
|
Thanks for the post. I see this is only private companies – I’m wondering how many government owned universities/hospitals are working on stem cells which can make a difference. Does anybody know actually how many stem cell centres there are around the world? Approx?
|
|
|
|
|
01-23-2006, 10:52 PM
|
#3 | |
|
Member
Join Date: May 2004
Posts: 50
|
Quote:
|
|
|
|
|
|
01-24-2006, 06:42 AM
|
#4 |
|
Senior Member
Join Date: Jun 2005
Location: Norway
Posts: 17,367
|
Sorry - your link would not open Pro-SCNT.
|
|
|
|
|
01-24-2006, 07:04 AM
|
#5 |
|
Senior Member
Join Date: May 2005
Location: Pakistan
Posts: 956
 |
Dear Leif Hope you will be fine. Never forget you are amongst my favourite CC Members. God bless you. Always smile and live happy.
Dear Young TriStem is already treating patients here in pakistan and tell some good results too. When i did contact to them they are hopeful for my good recovery as you know i am incomplete with L1 compression. They say that i can regain bladder bowel and sexual function. Though not much confident but still reasonable for recovery. I need to know from you is that is TriStem reliable and i should go for treatment? Hope you will advise best. God bless you and keep you happy and healthy longer. Jawaid |
|
|
|
|
01-27-2006, 01:32 AM
|
#6 |
|
Banned
Join Date: May 2003
Location: Jacksonville, FL
Posts: 6,840
|
Stem Cell Therapies and Regenerative Medicine: Current Applications
B-153R Stem Cell Therapies and Regenerative Medicine: Current Applications and Future Possibilities
Steven Edwards, Ph.D. Published December 2005 $3,950.00 for full report (add 15% for PDF version) Page and Chapter Pricing Available - Go to "Purchase On-line" 2002 Version Available  REPORT HIGHLIGHTS
($ Billions)  Source: BCC, Inc. INTRODUCTION In March 2002, BCC published its first study focused on stem cells and progenitor cell therapy. Since that time, stem cell and regenerative companies have had a difficult time because of a shortage of funding. However, new companies have sprung up, as new research prompts new avenues of exploration. The political climate for embryonic stem cells has changed. The Bush Administration maintains a ban in the U.S. on federal funding for research using newly established lines. However, California and Illinois have begun funding this research and others seem likely to follow. The House of Representatives has passed a bill reversing Bush's ban, and the Senate is likely to pass it. Meanwhile, other countries are making embryonic stem cell research a priority. For most of 2005, for instance, it seemed as if South Korean scientists had surpassed the rest of the world in the ability to generate patient-specific embryonic stem cells through nuclear transfer. It now appears that these results were fabricated; respectable peer-reviewed journals were taken in by the hoax because the achievements described were quite feasible, given similar results acheived in animal studies. Given these many changes taking place in regenerative medicine, it seems a good time to renew our study of this field. This comprehensive and cohesive technical market research report from BCC is set within the existing regulatory framework and takes into account not only technical accomplishments but also political and financial realities. The study, therefore, establishes the necessary context from which to make rational decisions regarding business decisions in this expanding field. SCOPE OF STUDY The report contains:
The information reported herein has been gathered from a variety of industry and other sources. The 10K forms and other SEC filings from public companies have been examined along with annual reports, catalogues, and press releases. The World Wide Web is a rich source of information, as almost every commercial concern now has its own Web page. Where appropriate, medical literature and scientific literature have served as a research source. We have also gathered statistical information from the U.S. government, the World Health Organization, and private foundations. Armed with the industry and statistical information garnered all of these sources, market participants were interviewed to fill in the gaps. ANALYST'S CREDENTIALS The author of this report, Steven Edwards, Ph.D., has a broad background in the biological and health sciences, and is well acquainted with advanced technology. He received his doctorate in biology from the University of California, San Diego. His thesis work centered on the expression of murine leukemia virus genes, and he was awarded a National Institutes of Health (NIH) postdoctoral fellowship to study neuroendocrinology at the Salk Institute. Subsequently, Dr. Edwards was a Research Associate at La Jolla Cancer Research Foundation (now Burnham Institute), where he studied developmental regulation of gene transcription in teratocarcinoma cells (cells similar to embryonic stem cells). Later, he was appointed assistant professor in the biochemistry department of Meharry Medical College (Nashville, TN). There he directed a research laboratory studying transcriptional regulation, supported by grants from the American Heart Association and the NIH. Dr. Edwards is now a medical industry analyst, and science writer and editor. He has been the editor of several BCC newsletters: Applied Genetics News, Drug Discovery/Technology News, Cell Therapy News, and Nano/Bio Convergence News, and is now editor of Biomolecular Diagnostic News. His journalistic work has also appeared in Massachusetts Institute of Technology's (MIT's) Technology Review, Diabetes Forecast, Genetic Engineering News, and other publications. He is a frequent contributor to RedzoneProfits (Website: www.redzoneprofits.com), an Internet-based investment newsletter that focuses on emerging technology companies. Dr. Edwards was the project analyst responsible for the BCC reports B-119 Cell Therapy and Tissue Engineering, Emerging Products (1998); B-127 Microelectronic Medical Implants, Products, Technology and Opportunity (1999); B-143 Bones and Joints: Drugs, Devices, and Regenerative Technologies (2000); Progenitor and Stem Cell Therapy: Current Uses and Future Possibilities (2002); B-162 Biomedical Applications of Nanoscale Devices (2003); and B-192 Beyond Chemotherapy: Battling Cancer with Biotechnology (2004). He is also the author of The Nanotech Pioneers: Where are they taking us?, a book due to be published by Wiley-VCH Verlag GmbH & Co. in January 2006. Dr. Edwards has served as vice president for technologies for Phaelixe, Inc., a consulting firm in Denver, CO. He has also consulted for a venture capital company, and has served as program chairman for several nanotech and nanobiotech conferences hosted by BCC. . OTHER RELEVANT BCC REPORTS AND PUBLICATIONS
TABLE OF CONTENTS INTRODUCTION XVIREASON FOR DOING THE STUDY XVISTUDY GOAL AND OBJECTIVES XVICONTRIBUTIONS OF THE STUDY AND FOR WHOM XVIISCOPE AND FORMAT XVIIMETHODOLOGY AND INFORMATION SOURCES XVIIIANALYST'S CREDENTIALS XVIIIOTHER RELEVANT BCC REPORTS AND PUBLICATIONS XIXBCC ONLINE SERVICES XXDISCLAIMER XXSUMMARY XXISummary Table: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS) XXIISummary Figure: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS) XXIIIOVERVIEW 1Table 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000 1GROWTH FACTORS AND CYTOKINES 1Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE 2Table 2 (CONTINUED) 3STEM AND PROGENITOR CELLS 3WORLDWIDE MARKETS FOR REGENERATIVE MEDICINE 4Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001 5Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES 6Table 5 AGING OF THE U.S. POPULATION 6CELL THERAPIES AS A SUBSTITUTE FOR TRANSPLANTS 7THE U.S. MARKET VERSUS THE REST OF THE WORLD 7The U.S. Market versus the (Continued) 8Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003 9DISTRIBUTION OF REVENUES AND EFFORT 10TYPES OF STEM OR PROGENITOR CELLS 11Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL 12Autologous Cells 13Allogeneic Cells 14UMBILICAL CORD BLOOD 14Table 8 A PARTIAL LIST OF DISEASES TREATED USING CORD BLOOD STEM CELLS 15EMBRYONIC STEM CELLS 16Embryonic Stem Cells (Continued) 17Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS 18Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO 18Table 10 (CONTINUED) 19Identification of Stem Cells 19Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY 20Therapeutic Cloning 20Therapeutic Cloning (Continued) 21Utility of ES Cells 22Ethical Considerations 23Position of the Catholic Church 24Position of the National Academy of Sciences 25Politics and Funding for Embryonic Stem Cell Research 26Politics and Funding for Embryonic Continued) 27NIH Guidelines 28NIH Guidelines (Continued) 29Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING 30Patents 30GERM CELLS 31WHAT MAKES A STEM CELL A STEM CELL? 31CELL-BASED GENE THERAPY 32U.S. REGULATION 33DEVICES 33Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION 34BIOLOGICALS 35Biologicals (Continued) 36ORPHAN PRODUCT STATUS 37INTERNATIONAL ISSUES 37OFFSHORE CELL-THERAPY TREATMENTS 38OFFSHORE CELL-THERAPY TREATMENTS (CONTINUED) 39APPLICATIONS FOR PROGENITOR CELL THERAPIES 40APPLICATIONS OF REGENERATIVE MEDICINE FOR BLOOD AND THE IMMUNE SYSTEM 40Figure 1 HEMATOPOIESIS 41APPLICATIONS OF REGENERATIVE CONTINUED) 42Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS 43Table 14 (CONTINUED) 44HARVESTING HEMATOPOIETIC STEM CELLS 44Bone Marrow 44Peripheral Blood Progenitor Cell Collection 45Umbilical Cord Blood 46Drug-Resistant Hematopoietic Stem Cells 46PRODUCTS AND SERVICES IN SUPPORT OF HEMATOPOIETIC STEM CELL TRANSFERS 47Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION 48CYTOKINES FOR STEM CELL THERAPY 49Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY 50G-CSF and GM-CSF 50AMD3100 51Erythropoietins 51MARKET OPPORTUNITIES FOR REGENERATIVE CYTOKINES 52Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS) 53Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS) 53HARVESTING AND STORAGE OF UMBILICAL CORD BLOOD 54Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES 55Market Opportunities for Umbilical Cord Blood Storage 56Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($) 57Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS) 58Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS) 58EXPANSION OF STEM CELLS 58Expansion of Stem Cells (Continued) 59Market Opportunities for Stem Cell Expansion. 60Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS) 60Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS) 61GRAFT-VERSUS-HOST DISEASE 61IMMUNE DEFICIENCIES 62Acquired Immunodeficiency Syndrome 63Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003 64Natural Resistance 64Current Therapies for AIDS 65Progenitor Cell Therapies for AIDS 65Market Opportunities for AIDS Therapies 66Table 23 SIZE OF THE AIDS/HIV EPIDEMIC 66SUMMARY: BLOOD AND IMMUNE DISEASES 67Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS) 67Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS) 68SKIN 68SKIN CELL PROGENITORS 69BURNS 69ULCERS 70ULCERS (CONTINUED) 71MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES 72MARKET OPPORTUNITIES FOR SKIN CELL THERAPIES (CONTINUED) 73Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS) 74Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS) 74BONE 74BONE FRACTURES 75Bone Metabolism 76Current Therapies 77Cell Therapies for Bone Fractures 77Growth Factors and Morphogenic Proteins 78Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING 79Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS 80Market Opportunities for Regenerative Therapies for Fractures and Spinal Fusions 80Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($) 81Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002 81Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS) 82Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS) 82CARTILAGE 83Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR 83MENISCUS REPAIR 83INJURIES OF THE KNEE 84INTERVERTEBRAL DISC REGENERATION 85MARKETS FOR CARTILAGE REPAIR 85Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS) 86Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS) 87CARDIOVASCULAR SYSTEM 87CONGESTIVE HEART FAILURE 88Current Therapies 88CORONARY HEART DISEASE 89Current Therapies 89CELL THERAPIES FOR CHF OR CORONARY DISEASE 89Cell Therapies for CHF or Coronary Disease (Continued) 90Cell Therapies for CHF or Coronary Disease (Continued) 91CARDIAC ARRYTHMIA 92Current Therapy 92Cell Therapies 93MARKET OPPORTUNITIES FOR CARDIOVASCULAR CELL THERAPIES 93Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND) 94TEETH 95HAIR 95BRAIN AND NERVOUS SYSTEM 96NEURAL STEM CELLS 97LYSOSOMAL STORAGE DISEASES 97DISORDERS OF THE MYELIN SHEATH 98SPINAL CORD INJURY 99Spinal Cord Injury (Continued) 100STROKE 101Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002 102PARKINSON'S DISEASE 103Cell Therapies 103Cell Therapies (Continued) 104The Market Opportunities for Regenerative Treatments to Treat Neural Disease 105EYES 105EYES (CONTINUED) 106Market Opportunities 107LIVER 108HUMAN CELL THERAPIES 109Human Cell Therapies (Continued) 110Markets for Regenerative Therapies for the Liver 111KIDNEY 111Potential Cell Therapies for Kidney Disease 112Market Opportunities for Regenerative Kidney Therapies 113DIABETES 113Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79 2003 AND 2025 (THOUSANDS) 114COMPLICATIONS OF DIABETES 115Current Treatments 115Edmonton Protocol 116STEM CELL THERAPIES 116Market Opportunities for Regenerative Diabetes Therapies 117REPRODUCTIVE MEDICINE 118MARKET OPPORTUNITIES FOR OOCYTE CRYOPRESERVATION 119Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION) 120Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION) 120PRODUCTS USED IN CELL THERAPY AND REGENERATIVE MEDICINE 121PRODUCTS USED FOR AMPLIFYING, CULTURING, OR TRANSFERRING STEM CELLS 121AASTROMREPLICELL SYSTEM 121MYOCATH PERCUTANEOUS DELIVERY SYSTEM 122PLURIX BIOREACTOR SYSTEM 123CYTOMATRIX 123CYTOKINES AND GROWTH FACTORS 124Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE 124AMD3100 125ARANESP 125BMP-7 126CHRYSALIN 126CTCE-0214 126CYT 99 007 127EPOGEN/PROCRIT 127INFUSE/INDUCTOS 128NEULASTA 128NEUMEGA 129NEUPOGEN 129OP-1 130REGRANEX GEL 131THYMOSIN BETA FOUR 131TUMOR GROWTH FACTOR ALPHA 132LIVING CELL THERAPIES 132HEMATOPOIETIC AND IMMUNE CELL THERAPIES 133Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT 133Highly Purified Hematopoietic Stem Cells 134HGTV-43 134MP Cells 135Procord 136SKIN 136Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY 136Apligraf 137Dermagraft 137EpiCel 138Hyalograft 3D 138Laserskin Autograft 138OrCel 139CARTILAGE 139Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE 139Carticel 139Cartilink 140Chondrogen 141Co.Don Chondrotransplant 141Co.Don Chondrotransplant DISC 141Hyalograft C 142ICX-PRO 142ICX-SKN 142NEURAL STEM CELLS 143HuCNS-SC 143MUSCLE 143Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS 143Biopace 143MyoCell 144Myocell VT 144Provacel 145OTHER MESENCHYMAL CELLS 145Prochymal 145Tissue Repair Cells - Aastrom Bioscience 146PANCREAS 146IxSC-1 146KIDNEY 147Renal Assist Device 147STEM CELL STORAGE 147BIOARCHIVE STEM CELL SYSTEM 147CCEL CELLULAR STORAGE FREEZER 148STRUCTURE OF THE INDUSTRY 149CYTOKINE AND GROWTH FACTOR COMPANIES 149Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES 149MARKET SHARES OF CYTOKINE AND GROWTH FACTOR COMPANIES 150Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES) 150PRODUCTS UNDER DEVELOPMENT 150Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS 151UMBILICAL CORD STEM CELL COMPANIES 151Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES 151CELL THERAPY COMPANIES 152Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES 152Table 46 (CONTINUED) 153Table 46 (CONTINUED) 154PATENTS 154PATENTS (CONTINUED) 155Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS 156Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005 157Table 48 (CONTINUED) 158Table 48 (CONTINUED) 159Table 48 (CONTINUED) 160ATTRITION 160Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE 161COMPANY PROFILES 162AASTROM BIOSCIENCES 162ADERANS RESEARCH INSTITUTE 162ADVANCED CELL TECHNOLOGY 163ADVANCED CELL THERAPEUTICS 164AMGEN 164ANORMED 165ATHERSYS 165BAXTER INTL. 166BEFUTUR BIOTECHNOLOGIES 166BIOHEART 167BIOMATRIX SCIENTIFIC GROUP 168BIOTISSUE, INC. 168BIOTISSUE TECHNOLOGIES AG 168BRAINSTORM CELL THERAPEUTICS 169CELLARTIS 170CELL BASED DELIVERY 170CELLERANT THERAPEUTICS 171CELLRESEARCH CORP. 171CELLULAR DYNAMICS 172CHEMOKINE THERAPEUTICS 172CO.DON AG 173CORCELL 173CORD BLOOD AMERICA 173CORD BLOOD REGISTRY 174CYGENICS 174CORDLIFE PTE, LTD./ CELL SCIENCES PTE, LTD. 174CYTOMATRIX 175CRYO-CELL INTL. 175CYTHERA 176CYTORI THERAPEUTICS 176DENTIGENIX, INC. 177ENCELLE 177ENZO BIOCHEM 178EXTENDFERTILITY 179FIDIA FARMACEUTICI SPA 179FREZER, INC. 179GENZYME BIOSURGERY 180GENVEC 181GERON 181HISTOSTEM 182INTERCYTEX 182INTERFACE BIOTECH A/S 183ISLET TECHNOLOGY 183ISTO TECHNOLOGIES 184IXION BIOTECHNOLOGY 185KALEIDOS PHARMACEUTICAL 185JOHNSON & JOHNSON 186LIFEBANK CRYOGENICS 186MEDRA 187MESOBLAST, LTD. 187MILTENYI BIOTEC GMBH 188MORPHOGENESIS 188NEOSTEM 189NEPHROS THERAPEUTICS 189NEURALSTEM BIOPHARMACEUTICALS 190NEURONYX 190NOVARTIS INTERNATIONAL AG 191NS GENE A/S 191ODONTIS 192ORGANOGENESIS 192ORTEC INTL. 193ORTHOLOGIC 193OSIRIS THERAPEUTICS 194PHARMA FRONTIERS 194PHARMASTEM THERAPEUTICS 195PLURISTEM LIFE SYSTEMS 195PRIMEGEN BIOTECH, LLC 196PROGENITOR CELL THERAPY 196PRONEURON BIOTECHNOLOGIES 197REGENERX BIOPHARMACEUTICALS 197RENEURON 198SANERON CCEL THERAPEUTICS, INC. 198STEMCELLS, INC. 199STEMCELL PHARMA, INC. 199STEM CELL SCIENCES 200STEM CELL THERAPEUTICS CORP. 200STEM CELL THERAPY INTL. 201THERMOGENESIS 202TISSERA 202U.S. BIODEFENSE, INC. 202VESTA THERAPEUTICS 203VIACELL 203WICELL RESEARCH INSTITUTE 204APPENDIX 205GLOSSARY OF TERMS AND ABBREVIATIONS 205GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 206GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 207GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 208GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 209GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 210GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 211GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 212GLOSSARY OF TERMS AND ABBREVIATIONS (CONTINUED) 213 LIST OF TABLES Summary Table: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, THROUGH 2010 ($ BILLIONS) XXIITable 1 PERCENT OF PERSONS USING PRESCRIPTION DRUGS IN THE PAST MONTH IN THE U.S., 1999-2000 1Table 2 SELECTED CYTOKINES OR GROWTH FACTORS RELEVANT TO REGENERATIVE MEDICINE 2Table 3 LEADING CAUSES OF DEATH IN THE U.S., 2001 5Table 4 PREVALENCE OF MEDICAL CONDITIONS IN THE U.S. WITH POTENTIAL CELL THERAPIES 6Table 5 AGING OF THE U.S. POPULATION 6Table 6 POPULATION OF COUNTRIES OF THE EUROPEAN UNION, 2003 9Table 7 DESCENDANTS OF THE HUMAN MESENCHYMAL STEM CELL 12Table 8 A PARTIAL LIST OF DISEASES TREATED USING 15CORD BLOOD STEM CELLS 15Table 9 DERIVATION OF BODY TISSUE TYPES FROM GERM LAYERS 18Table 10 CELL TYPES DERIVED FROM EMBRYONIC STEM CELLS IN VITRO 18Table 11 MARKERS OF PLURIPOTENT CELLS IN MOUSE, MAN, AND MONKEY 20Table 12 EMBRYONIC STEM CELL LINES THAT MEET NIH FUNDING REQUIREMENTS, WHICH ARE AVAILABLE FOR SHIPPING 30Table 13 FOOD AND DRUG ADMINISTRATION BODIES INVOLVED IN IMPLANT REGULATION 34Table 14 A PARTIAL LIST OF DISEASES TREATED WITH HEMATOPOIETIC STEM CELLS 43Table 15 COMMERCIAL OPPORTUNITIES FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION 48Table 16 APPROVED BIOPHARMACEUTICALS FOR THE REGENERATION OF BLOOD AND IMMUNE CELLS AFTER CHEMOTHERAPY 50Table 17 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, THROUGH 2010 ($ MILLIONS) 53Table 18 COMMERCIAL UMBILICAL CORD BLOOD STORAGE COMPANIES 55Table 19 FEES CHARGED BY MAJOR UMBILICAL CORD BLOOD BANKS, 2005 ($) 57Table 20 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, THROUGH 2010 ($ MILLIONS) 58Table 21 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, THROUGH 2010 ($ MILLIONS) 60Table 22 AQUIRED IMMONDEFICIENCY CASES REPORTED BY YEAR IN THE U.S., 1985-2003 64Table 23 SIZE OF THE AIDS/HIV EPIDEMIC 66Table 24 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS) 67Table 25 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, THROUGH 2010 ($ MILLIONS) 74Table 26 GROWTH FACTOR PRODUCTS FOR BONE HEALING 79Table 27 GROWTH FACTORS DEVELOPED BUT NOT YET APPROVED FOR BONE INDICATIONS 80Table 28 SPINAL FUSION DATA, U.S. 1998-2002 ($) 81Table 29 NUMBER OF LOWER LEG FRACTURE, 1998-2002 81Table 30 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS) 82Table 31 PRODUCTS FOR REGENERATIVE CARTILAGE REPAIR 83Table 32 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, THROUGH 2010 ($ MILLIONS) 86Table 33 PREVALENCE OF HEART DISEASE IN U.S. ADULTS (18 YEARS AND OVER), 2002 (THOUSAND) 94Table 34 DEATH RATES PER 100,000 FROM CEREBROVASCULAR DISEASE (STROKE) IN THE U.S., 1960 AND 2002 102Table 35 GLOBAL PREVALENCE OF DIABETES IN EUROPE, AGES 20 TO 79, 2003 AND 2005 (THOUSANDS) 114Table 36 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, THROUGH 2010 ($ MILLION) 120Table 37 CYTOKINES AND GROWTH FACTORS IN REGENERATIVE MEDICINE 124Table 38 LIVING BLOOD AND IMMUNE CELL THERAPEUTIC PRODUCTS IN DEVELOPMENT 133Table 39 LIVING SKIN EQUIVALENTS USED THERAPEUTICALLY 136Table 40 LIVING-CELL PRODUCTS USED THERAPEUTICALLY TO REPAIR CARTILAGE 139Table 41 MUSCLE CELLS USED AS THERAPEUTIC PRODUCTS 143Table 42 COMPANIES SUPPLYING APPROVED CYTOKINE OR GROWTH FACTOR THERAPIES 149Table 43 RANKINGS AND MARKET SHARES OF COMPANIES FOR CYTOKINES AND GROWTH FACTORS IN 2004 (REVENUES) 150Table 44 COMPANIES DEVELOPING GROWTH FACTOR OR CYTOKINE PRODUCTS 151Table 45 2004 WORLDWIDE MARKET RANKINGS FOR UMBILICAL CORD STEM CELL STORAGE COMPANIES 151Table 46 FOCUS OF STEM AND PROGENITOR CELL THERAPY COMPANIES 152Table 47 U.S. PATENT APPLICATIONS FROM JANUARY 1, 2001 THROUGH SEPTEMBER 8, 2005, WITH SELECTED STEM CELL SEARCH TERMS 156Table 48 SELECTED U.S. STEM CELL PATENTS ISSUED BETWEEN JANUARY 2002 AND SEPTEMBER 2005 157Table 49 DISAPPEARING NAMES IN REGENERATIVE MEDICINE 161 LIST OF FIGURES Summary Figure: GLOBAL FORECAST OF REVENUES FOR STEM CELL AND CYTOKINE THERAPIES IN REGENERATIVE MEDICINE, 2003-2010 ($ BILLIONS) XXIIIFigure 1 HEMATOPOIESIS 41Figure 2 SALES OF THERAPEUTIC REGENERATIVE CYTOKINES FOR BLOOD AND IMMUNE DISEASES, 2003-2010 ($ MILLIONS) 53Figure 3 WORLDWIDE REVENUES FROM CORD BLOOD HARVEST AND STORAGE, 2003-2010 ($ MILLIONS) 58Figure 4 WORLDWIDE REVENUES FROM EXPANSION AND CULTURE OF THERAPEUTIC STEM CELLS, 2003-2010 ($ MILLIONS) 61Table 5 GLOBAL FORECAST OF REVENUES FOR BLOOD AND IMMUNE DISEASES ($ MILLIONS) 68Figure 6 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE WOUND THERAPY PRODUCTS, 2003-2010 ($ MILLIONS) 74Figure 7 GLOBAL FORECAST OF REVENUES FOR REGENERATIVE THERAPIES FOR SPINAL FUSIONS AND BONE FRACTURES ($ MILLIONS) 82Figure 8 GLOBAL FORECAST OF SALES OF CELL THERAPY PRODUCTS TO REPAIR CARTILAGE, 2003-2010 ($ MILLIONS) 87Figure 9 GLOBAL FORECAST OF REVENUES DERIVED FROM OOCYTE STORAGE, 2003-2010 ($ MILLION) 120
__________________
"There’s far too much unthinking respect given to authority,” Molly Ivins explained; “What you need is sustained outrage.” Kerr, Keirstead, McDonald, Stice and Jun Yan courageously work on ESCR to Cure SCI. Divisiveness comes from not following Christopher Reeve's ESCR lead. Young does ASCR. [I]I do not tear down CRPA, I ONLY make peopl |
|
|
|
|
01-27-2006, 01:58 AM
|
#7 | |
|
Administrator
Join Date: Jul 2001
Location: New Brunswick, NJ, USA
Posts: 37,975
|
Jawaid,
I don't know enough about Tristem to comment definitively. I have not seen any evidence that they have any evidence to back up claims that their treatments will be beneficial for spinal cord injury. Wise. Quote:
|
|
|
|
|
|
01-27-2006, 07:44 AM
|
#8 |
|
Senior Member
Join Date: May 2005
Location: Pakistan
Posts: 956
|
Dear Dr. Young
Can you tell me something about the treatments of TriStem? Their procedure is called Retrodifferentation i think. What is this? Are they using Umbilical Cord Cells or any other type of cells? How much this way of treatment can be fruitful for Spinal injury? Jawaid |
|
|
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Stem cell study gets personal | Wise Young | Life | 14 | 11-19-2010 05:17 AM |
| Stem cell research in the U.S. and the world during the past decade | Wise Young | Cure | 0 | 01-18-2005 02:52 AM |
| Illinois comptroller to unveil stem cell proposal | Carl R | Cure | 21 | 12-02-2004 03:01 PM |
| World-wide stem cell research | Wise Young | Cure | 4 | 04-27-2003 07:16 PM |
Linear Mode
